| Literature DB >> 36042948 |
Gang Yuan1, Yao He1, Qing-Hua Cao2, Mi-Mi Tang3, Zong-Lin Xie1, Yun Qiu1, Zhi-Rong Zeng1, Sui Peng1,4,5, Min-Hu Chen1.
Abstract
Background: This study explored the diagnostic performance of visceral adiposity to predict the degree of intestinal inflammation and fibrosis.Entities:
Keywords: Crohn’s disease; computed tomography enterography; intestinal fibrosis; visceral fat
Year: 2022 PMID: 36042948 PMCID: PMC9420045 DOI: 10.1093/gastro/goac044
Source DB: PubMed Journal: Gastroenterol Rep (Oxf)
Figure 1.The 3D imaging of both visceral fat and subcutaneous fat (A), visceral fat (B), and subcutaneous fat (C) on the A.K software
Figure 2.The flowchart of the study
Demographic and clinical characteristics of 48 patients with small intestinal Crohn’s disease
| Characteristic | Value ( |
|---|---|
| Male, | 37 (77.1) |
| Age, years, mean ± SD | 31.8 ± 11.5 |
| Disease duration, months, median (IQR) | 36.0 (12.0, 60.0) |
| Time interval between CTE and surgery, days, mean ± SD | 22.5 ± 18.9 |
| Smoking, | 8 (16.7) |
| BMI, kg/m2, mean ± SD | 17.23 ± 2.47 |
| Montreal classification, | |
| A1/A2/A3 | 2/38/8 |
| L1/L2/L3/L4 | 34/6/8/0 |
| B1/B2/B3 | 0/35/13 |
| Surgery type, | |
| Ileocolonic resection | 30 (62.5) |
| Partial small bowel resection | 18 (37.5) |
| Most severe disease location, | |
| Ileocecum | 13 (27.1) |
| Terminal ileum | 11 (22.9) |
| Ileum + jejunum | 24 (50.0) |
| Treatment before surgery | 23 (47.9) |
| Crohn disease activity index, mean ± SD | 210.0 ± 88.6 |
| C-reactive protein, mg/L, mean ± SD | 33.9 ± 40.3 |
| Erythrocyte sedimentation rate, mm/h, mean ± SD | 39.0 ± 25.4 |
SD, standard deviation; IQR, interquartile range; BMI, body mass index; CTE, computed tomography enterography.
The specific treatments are shown in the Supplementary material.
CTE findings, fat parameter findings, and clinical features in different grades of intestinal inflammation and fibrosis
| Factor | Inflammation |
| Fibrosis |
| ||||
|---|---|---|---|---|---|---|---|---|
| Grade 2 ( | Grade 3 ( | Grade 4 ( | Grade 2 ( | Grade 3 ( | Grade 4 ( | |||
| VF/SF ratio | 1.3 ± 0.7 | 0.8 ± 0.6 | 0.9 ± 0.5 | 0.131 | 0.6 ± 0.3 | 1.0 ± 0.6 | 1.4 ± 0.6 | 0.004 |
| Wall thickness, | 0.567 | 0.466 | ||||||
| >7 mm | 9 (100.0) | 7 (87.5) | 29 (93.5) | 15 (100.0) | 18 (90.0) | 12 (92.3) | ||
| ≤7 mm | 0 (0.0) | 1 (12.5) | 2 (6.5) | 0 (0.0) | 2 (10.0) | 1 (7.7) | ||
| Narrowed diameter | 5.0 (4.0, 7.0) | 4.0 (3.5, 5.5) | 4.0 (2.0, 5.0) | 0.382 | 5.0 (2.0, 6.0) | 5.0 (3.0, 6.5) | 4.0 (3.0, 5.0) | 0.453 |
| Upstream dilatation diameter | 30.0 (17.0, 32.0) | 33.0 (27.5, 43.5) | 35.0 (23.0, 47.0) | 0.333 | 33.0 (17.0, 50.0) | 30.5 (23.5, 40.5) | 32.0 (24.0, 42.0) | 0.969 |
| ND ratio | 20.3 ± 6.7 | 13.5 ± 5.0 | 15.9 ± 12.0 | 0.378 | 18.3 ± 11.7 | 17.8 ± 11.4 | 11.6 ± 4.7 | 0.163 |
| Hypervascularity, | 9 (100.0) | 7 (87.5) | 30 (96.8) | 0.396 | 15 (100.0) | 18 (90.0) | 13 (100.0) | 0.232 |
| Fat stranding, | 8 (88.9) | 7 (87.5) | 31 (100.0) | 0.148 | 15 (100.0) | 18 (90.0) | 13 (100.0) | 0.232 |
| Target sign, | 8 (88.9) | 8 (100.0) | 30 (96.8) | 0.472 | 14 (93.3) | 19 (95.0) | 13 (100.0) | 0.659 |
| Lymphadenopathy, mm | 7.0 ± 2.3 | 6.0 ± 2.4 | 7.2 ± 4.0 | 0.698 | 7.3 ± 3.0 | 6.8 ± 4.2 | 6.8 ± 2.9 | 0.741 |
| Male, | 6 (66.7) | 5 (62.5) | 26 (83.9) | 0.313 | 12 (80.0) | 14 (70.0) | 11 (84.6) | 0.589 |
| Age | 26.0 (23.0, 33.0) | 35.0 (30.5, 45.0) | 29.0 (24.0, 34.0) | 0.105 | 28.0 (24.0, 34.0) | 32.5 (24.5, 37.5) | 31.0 (25.0, 35.0) | 0.625 |
| BMI | 18.6 (17.3, 19.5) | 15.8 (14.4, 18.3) | 17.0 (15.0, 18.3) | 0.167 | 17.1 (14.9, 18.7) | 17.4 (16.2, 18.9) | 15.1 (14.9, 17.3) | 0.216 |
| CDAI | 159.7 ± 82.8 | 211.4 ± 41.7 | 224.2 ± 95.4 | 0.158 | 208.6 ± 84.6 | 211.6 ± 80.5 | 209.0 ± 108.5 | 0.994 |
| ESR | 19.0 (6.0, 51.0) | 34.5 (29.5, 52.5) | 37.0 (24.0, 51.0) | 0.185 | 37.0 (17.0, 45.0) | 37.0 (14.0, 51.0) | 37.0 (29.0, 54.0) | 0.550 |
| CRP | 33.0 (13.5, 65.9) | 14.7 (2.5, 34.5) | 13.7 (10.1, 44.1) | 0.737 | 13.5 (7.3, 27.0) | 13.7 (7.0, 83.4) | 22.7 (13.5, 42.9) | 0.769 |
| PLT, 109/L | 333.8 ± 163.6 | 329.9 ± 93.8 | 317.9 ± 90.4 | 0.908 | 345.1 ± 70.9 | 298.8 ± 109.3 | 344.3 ± 130.7 | 0.404 |
| HCT, % | 34.5 ± 8.1 | 33.9 ± 4.9 | 33.6 ± 6.1 | 0.928 | 35.7 ± 5.4 | 32.5 ± 6.7 | 33.6 ± 6.2 | 0.329 |
| Disease duration | 36.0 (10.0, 54.0) | 18.0 (3.5, 30.0) | 36.0 (12.0, 72.0) | 0.132 | 48.0 (10.0, 60.0) | 30.0 (11.0, 63.0) | 24.0 (12.0, 60.0) | 0.903 |
| Anemia, | 4 (44.4) | 3 (37.5) | 19 (61.3) | 0.392 | 7 (46.7) | 10 (50.0) | 9 (69.2) | 0.434 |
BMI, body mass index; CDAI, clinical disease activity index; CRP, C-reactive protein; CTE, computed tomography enterography; ESR, erythrocyte sedimentation rate; HCT, red blood cell specific volume; IQR, interquartile range; ND ratio = 100 × narrowed diameter/upstream dilatation diameter; PLT, platelet; VF/SF ratio, the volume ratio of abdominal visceral fat to subcutaneous fat.
The data do not follow the normal distribution.
Multi-variant binomial logistic regression analysis for predicting severe fibrosis and inflammatory
| Feature | Odds ratio (95% CI) |
|
|---|---|---|
| Fibrosis score (2/3 vs 4) | ||
| VF/SF volume ratio | 1.20 (1.05–1.38) | 0.009 |
| ND ratio, increase by one unit | 0.90 (0.82–0.99) | 0.034 |
| Inflammatory score (2/3 vs 4) | ||
| Gender (female vs male) | 0.24 (0.05–1.12) | 0.070 |
| Anemia (yes vs no) | 3.18 (0.83–12.20) | 0.092 |
CI, confidence interval; VF/SF volume ratio, the volume ratio of abdominal visceral fat to subcutaneous fat; ND ratio = 100 × narrowed diameter/upstream dilatation diameter.
The value of VF/SF volume ratio × 10; considering that the VS/VF value is low to make the OR value vary widely by one unit in the multivariate analysis, all values of the VF/SF volume ratio here are multiplied by 10.
Figure 3.Clinical data of a typical case with severe fibrotic stenosis. The 44-year-old female patient suffered from Crohn’s disease for >12 years with fecal incontinence and abdominal pain. Computed tomography enterography (CTE) before surgery showed that there was intestinal fistula and perianal abscess. The inflammatory score is Grade 2 and fibrosis score is Grade 4 based on histological pathology. (A) The red area shows quantitative 3D image fat signaling with A.K. software. (B) and (C) show the subcutaneous and visceral fat signaling on A.K. software, respectively. (D) and (E) show the intestinal stricture on axial CT and cross-sectional CT. The white hollow arrow shows the stricture and the white solid arrow shows the prestenotic dilation. (F) Histological specimen (corresponding area of the stricture) by hematoxylin and eosin (H&E) staining shows massive fibrosis in the intestinal wall.
Figure 4.Clinical data of a typical case with severe inflammatory stenosis. A 53-year-old man suffered from Crohn’s disease for >4 years with fever and abdominal pain. CTE showed that there was terminal ileum stenosis and bowel wall thickening. The inflammatory score is Grade 4 and fibrosis score is Grade 2 based on histological pathology. (A) The red area shows quantitative 3D image fat signaling with A.K. software. (B) and (C) show the subcutaneous and visceral fat signaling on A.K. software, respectively. (D) and (E) show the intestinal stricture on coronal CT and cross-sectional CT. The white hollow arrow shows the stricture. (F) Histological specimen (corresponding area of the stricture) by hematoxylin and eosin (H&E) staining shows inflammatory cells infiltrate the mucosa and submucosa (A color version of this figure appears in the online version of this article).
Figure 5.The correlation of the volume ratio of abdominal visceral fat to subcutaneous fat (VF/SF ratio) (A), the stenosis diameter/upstream intestinal dilatation diameter (ND ratio) (B) with different fibrosis scores of intestinal strictures. The overall P-values of VF/VS ratio and ND ratio among three subgroups are P < 0.001 and P = 0.109, respectively.
Figure 6.Receiver-operating characteristic curves (A) and decision curves (B) of VF/SF ratio, ND ratio, and combined (VF/SF + ND) ratio. The decision curve analysis reflected the net benefit of models. The horizontal lines across indicate that all samples were negative and none of them was intervened. The slanting one means that all the samples were positive and received the intervention, and the net benefit is a negative-slope backslash. The curves of net benefit of each model are compared and the slowest slope of the curve at the positive area indicates that the net benefit of the model is the best. ND ratio, 100 × narrow intestinal tube diameter/dilated intestinal segment diameter; VF/SF ratio, the volume ratio of abdominal visceral fat to subcutaneous fat.
The diagnostic performance of each model for severe fibrosis (Grade 4)
| Model | AUC (95% CI) | Sensitivity | Specificity | Accuracy | PPV | NPV |
|---|---|---|---|---|---|---|
| VF/SF ratio + ND ratio | 0.804 (0.660–0.949) | 61.5 (8/13) | 91.4 (32/35) | 83.3 (40/48) | 72.7 (8/11) | 86.5 (32/37) |
| VF/SF ratio | 0.760 (0.619–0.902) | 76.9 (10/13) | 68.6 (24/35) | 70.8 (34/48) | 47.6 (10/21) | 88.9 (24/27) |
| ND ratio | 0.673 (0.523–0.822) | 76.9 (10/13) | 68.6 (24/35) | 70.8 (34/48) | 47.6 (10/21) | 88.9 (24/27) |
ND ratio, 100 × narrow intestinal tube diameter/dilated intestinal segment diameter; VF/SF ratio, the volume ratio of abdominal visceral fat to subcutaneous fat; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval; AUC, the area under the curve.